Medgenics Receives Orphan Drug Designation from FDA for INFRADURE Biopump to Treat Hepatitis D
11:31 EDT 20 Jun 2012 | Businesswire
This article has expired, however you can still
download the PDF.
Preview:
Medgenics, Inc. (NYSE MKT: MDGN and AIM: MEDU, MEDG), the
developer of BiopumpTM, a novel technology for the sustained
production and delivery of therapeutic proteins in patients using their
own tissue, today announced that its ...
Other Sources for this Article
Medgenics, Inc.
Dr. Andrew L. Pearlman, +972 4 902 8900
andrew.pearlman@medgenics.com
or
LHA
Anne
Marie Fields, 212-838-3777
afields@lhai.com
@LHA_IR_PR
or
Abchurch
Communications
Adam Michael/Joanne Shears/Jamie Hooper
+44 207
398 7719
jamie.hooper@abchurch-group.com
or
Nomura
Code Securities (NOMAD & Joint Broker)
Jonathan Senior/Giles
Balleny,
+44 207 776 1200
or
SVS Securities plc (Joint
Broker)
Alex Mattey/Ian Callaway
+44 207 638 5600
More From BioPortfolio on "Medgenics Receives Orphan Drug Designation from FDA for INFRADURE Biopump to Treat Hepatitis D"
Biotech & Healthcare Channels
World News
Life Science Events
Corporate Database
Market Reports
Categories
Search BioPortfolio:
